Characteristics of PLWH (people living with HIV) sample that answered the questionnaire (n (%); N=129 PLWH) and their answers when asked if they knew the monthly price of their treatment (N=128 as one was not on antiretroviral treatment)
| Characteristics of the sample (N=129; %) | ‘Do you know the monthly price of your ART?’ (N=128 as one PLWH was not on ART at the time of the survey) | |
| Answers*: Yes (n, %) | ||
| Age (years) | ||
| 20–39 years | 28 (21.7) | 15 (55.6) |
| 40–59 years | 79 (61.3) | 53 (67.1) |
| ≥60 years | 19 (14.7) | 15 (79.0) |
| Do not wish to answer | 3 (2.3) | 1 (33.3) |
| Sex | ||
| Male | 84 (65.1) | 59 (70.2) |
| Female | 45 (34.9) | 25 (56.8) |
| Place of birth | ||
| France | 70 (54.3) | 57 (81.4) |
| Sub-Saharan Africa | 35 (27.1) | 15 (44.1) |
| Others† | 19 (14.7) | 9 (47.4) |
| Do not wish to answer | 5 (3.9) | 3 (60.0) |
| Living as a couple | ||
| Yes | 63 (48.8) | 45 (72.6) |
| No | 66 (51.2) | 39 (59.1) |
| Having children | ||
| Yes | 66 (51.2) | 38 (58.5) |
| No | 63 (48.8) | 46 (73.0) |
| Do you consider yourself as | ||
| MSM | 54 (41.8) | 42 (77.8) |
| Heterosexual | 65 (50.4) | 39 (60.9) |
| Do not wish to answer | 10 (7.8) | 3 (30.0) |
| Education | ||
| No qualification | 17 (13.2) | 10 (58.8) |
| Lower secondary school diploma | 27 (20.9) | 15 (57.7) |
| High school diploma | 17 (13.2) | 11 (64.7) |
| University degree | 68 (52.7) | 48 (70.6) |
| In employment | ||
| Yes | 86 (66.7) | 58 (67.4) |
| No | 43 (33.3) | 26 (61.9) |
| Financial well-being | ||
| Very difficult | 44 (34.1) | 24 (55.8) |
| Somewhat difficult | 34 (26.4) | 26 (76.5) |
| Not difficult | 48 (37.2) | 33 (68.8) |
| Do not wish to answer | 3 (2.3) | 1 (33.3) |
| Disabled persons’ allowances | ||
| Yes | 19 (14.7) | 11 (57.9) |
| No | 98 (76.0) | 66 (68.0) |
| Do not know | 12 (9.3) | 7 (58.3) |
| Time since diagnosis of HIV infection (years) | ||
| 0–9 | 59 (45.7) | 36 (62.1) |
| 10–19 | 34 (26.4) | 24 (70.6) |
| 20–29 | 32 (24.8) | 22 (68.8) |
| 30–39 | 4 (3.1) | 2 (50.0) |
| Duration of ART (years) | ||
| 0–9 | 69 (53.5) | 43 (62.3) |
| 10–19 | 32 (25.4) | 24 (75.0) |
| 20–29 | 25 (19.8) | 16 (64.0) |
| Do not know | 3 (1.3) | 1 (50.0) |
| Reported ART regimen‡ | ||
| Triple therapy | 94 (73.4) | 66 (70.2) |
| Dual therapy | 12 (9.4) | 7 (58.3) |
| Mono therapy | 3 (2.4) | 2 (66.7) |
| Others§ | 4 (3.1) | 1 (25.0) |
| Do not know | 15 (11.7) | 8 (53.3) |
| Number of changes in ART‡ | ||
| Never | 23 (18.0) | 13 (56.5) |
| 1–2 | 50 (39.0) | 35 (70.0) |
| 3–4 | 33 (25.8) | 22 (66.7) |
| 5 or more | 12 (9.4) | 11 (91.7) |
| Do not know | 10 (7.8) | 3 (30.0) |
| Reported nadir of CD4 cell count | ||
| <200/mm3 | 33 (25.6) | 25 (75.8) |
| 201–500/mm3 | 28 (21.7) | 20 (71.4) |
| >500/mm3 | 22 (17.0) | 18 (81.8) |
| Do not know | 46 (35.7) | 21 (46.7) |
| Reported last CD4 cell count | ||
| <200/mm3 | 12 (9.3) | 10 (83.3) |
| 201–500/mm3 | 19 (14.7) | 13 (68.4) |
| >500/mm3 | 57 (44.2) | 44 (77.2) |
| Do not know | 41 (31.8) | 17 (42.5) |
| Reported last HIV plasma viral load | ||
| Undetectable | 105 (81.4) | 68 (64.8) |
| Not undetectable | 10 (7.8) | 8 (80.0) |
| Do not know | 14 (10.8) | 8 (61.5) |
| Reported active hepatitis coinfection | ||
| HBV | 5 (3.9) | 3 (60.0) |
| HCV | 9 (7.0) | 5 (55.6) |
| HBV+HCV | 1 (0.8) | 1 (100) |
| None | 114 (88.3) | 75 (66.4) |
| Current or past enrollment in clinical trial | ||
| Yes | 32 (24.8) | 23 (71.9) |
| No | 97 (75.2) | 61 (63.5) |
| Health Insurance status | ||
| Standard¶ | 99 (76.7) | 70 (70.7) |
| Resource constricted** | 30 (23.3) | 14 (48.3) |
| Usage of generic drugs (other than ART) | ||
| Yes | 103 (79.8) | 76 (73.8) |
| No | 26 (20.2) | 8 (32.0) |
| Contact with PLWH’s associations | ||
| Yes | 15 (11.6) | 8 (53.3) |
| No | 114 (88.4) | 76 (67.3) |
*Answers could be either ‘yes’ or ‘no’, 84/128 answered ‘yes’.
†Others=rest of Europe, Caribbean, North Africa, South America, South-East Asia, Far East.
‡N=128, as 1 out of the 129 respondents was not on ART .
§Others=multiple therapy and currently on clinical trials’ ARV drugs.
¶Standard: French Social Security+additional private coverage and French Social Security coverage alone.
**Universal Health Coverage (CMU)+top up CMU, State medical aid (AME) and Hospitals access to Healthcare (PASS) for people excluded from health insurance.
AME, aide médicale de l’état; ART, antiretroviral therapy; CMU, Couverture médicale universelle; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; MSM, men who have sex with men; PASS, Permanence d’accès aux soins; PLWH, people living with HIV.